// App-Quantinova.ai

1017 : Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

Researchers

Presenter

  • Kenji Tamura

Principal Investigators

  • Jun Hashimoto

  • Hitoshi Tsuda

  • Shinji Ohno

  • Katsumasa Kuroi

  • Tamie Sukigara

  • Yasuhiro Fujiwara

  • Kenjiro Aogi

  • Satoru Shimizu

  • Hiroji Iwata

  • Norikazu Masuda

  • Naohito Yamamoto

  • Kenichi Inoue

  • Masashi Andoh

  • Masayuki Yoshida

  • Hideko Yamauchi

Medical Centers

  • Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

  • Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan

  • Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan

  • National Defense Medical College, Department of Basic Pathology, Tokorozawa, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, JapanDepartment of Pathology and Laboratories, National Cancer Center Hospital, Tsukiji, Tokyo, JapanDepartment of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

  • Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan

  • Department of Gastroenterology, Shikoku Cancer Center, Mtatsuyama, Japan

  • Chiba Cancer Center, Chiba, Japan

  • Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

  • Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Epidermal growth factor receptor

  • Excision repair cross-complementation group 1

  • Human epidermal growth factor receptor 2

  • Zinc finger E-box binding homeobox 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Adrucil injection

  • Fluorouracil

  • Carboplatin

  • Epirubicin

  • Paclitaxel

Outcome

  • Positive

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved